-
Something wrong with this record ?
COVID-19 Vaccine ChAdOx1-S [recombinant] : 26 February 2021
- Published
- [Geneva] : World Health Organization, [2021]
- Pagination
- 6 stran
Language English Country Switzerland
- Conspectus
- Veřejné zdraví a hygiena
- NML Fields
- veřejné zdravotnictví
- preventivní medicína
- infekční lékařství
- NML Publication type
- publikace WHO
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vector vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine
| Owner | Details | Services |
|---|---|---|
| NLK | NLK Shelf no. online [0] | see E-resources |
- 000
- 00000nam a2200000 i 4500
- 001
- MED00206881
- 003
- CZ-PrNML
- 005
- 20210415201735.0
- 008
- 210415s2021 sz eo 000 0|eng||
- 009
- W
- 040 __
- $a ABA008 $b cze $d ABA008 $e rda
- 041 0_
- $a eng
- 044 __
- $a sz
- 072 _7
- $a 614 $x Veřejné zdraví a hygiena $2 Konspekt $9 14 $7 sk136314
- 245 00
- $a COVID-19 Vaccine ChAdOx1-S [recombinant] : $b 26 February 2021
- 246 12
- $a AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine
- 264 _1
- $a [Geneva] : $b World Health Organization, $c [2021]
- 300 __
- $a 6 stran
- 336 __
- $a text $b txt $2 rdacontent
- 337 __
- $a počítač $b c $2 rdamedia
- 338 __
- $a online zdroj $b cr $2 rdacarrier
- 347 __
- $a textový soubor $b PDF $2 rda
- 520 3_
- $a The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vector vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
- 650 07
- $a veřejné zdravotnictví $7 nlk20040148357 $2 mednas
- 650 07
- $a preventivní medicína $7 nlk20050173135 $2 mednas
- 650 07
- $a infekční lékařství $7 nlk20040148021 $2 mednas
- 650 07
- $a vakcíny proti COVID-19 $7 D000086663 $2 czmesh
- 650 07
- $a COVID-19 $x prevence a kontrola $7 D000086382 $2 czmesh
- 650 07
- $a vakcinace $7 D014611 $2 czmesh
- 655 _4
- $a publikace WHO $7 nlk20040156070
- 856 41
- $u https://www.who.int/publications/m/item/chadox1-s-recombinant-covid-19-vaccine $y plný text volně přístupný
- 910 __
- $a ABA008 $b online $y 0
- 990 __
- $a 20210415201732 $b ABA008
- 991 __
- $a 20210415201732 $b ABA008
- 999 __
- $a ok $b medvik21 $g 1642210 $s 222790
- BAS __
- $a 30 $a 49
- LZP __
- $b 2021online
